SK Biopharmaceuticals Co (326030.KS) Stock Price
SK Biopharmaceuticals Co Price
Revenue has compounded at 25.7% per year over the past 9 years to 706.74 B KRW. Earnings per share have grown at 42.4% per year over the last 4 years. SK Biopharmaceuticals Co's net margin stands at 37.8%, up from 15.5% several years earlier. Analysts set a median price target of 158,100.00 KRW, implying 114.2% above the current price. Of 22 analysts, 18 rate the stock a buy — an overall Buy consensus.
SK Biopharmaceuticals Co stock price
SK Biopharmaceuticals Co business model & stock analysis
Frequently asked questions about SK Biopharmaceuticals Co
The business model of SK Biopharmaceuticals Co Ltd revolves around the development and commercialization of innovative pharmaceutical products. As a global biopharmaceutical company, SK Biopharmaceuticals focuses on researching, discovering, and developing novel treatments for various diseases. This includes conducting rigorous clinical trials, obtaining regulatory approvals, and engaging in strategic partnerships for the commercialization of their products. With a strong emphasis on research and development, SK Biopharmaceuticals aims to bring forth cutting-edge therapies to improve patients' lives and address unmet medical needs.
SK Biopharmaceuticals Co Ltd is primarily active in the pharmaceutical industry.
The main competitors of SK Biopharmaceuticals Co Ltd in the market include major players like Johnson & Johnson, Pfizer Inc., and Novartis AG. These companies, along with SK Biopharmaceuticals, are engaged in the research, development, and commercialization of innovative biopharmaceutical products. With its strong portfolio and market presence, SK Biopharmaceuticals competes fiercely and continuously strives to maintain its position among these industry giants.
SK Biopharmaceuticals Co Ltd is a leading biopharmaceutical company with a rich history and background. Established in 1993, the company specializes in research, development, and manufacturing of innovative therapeutics. Headquartered in South Korea, SK Biopharmaceuticals has expanded its global presence through strategic partnerships and collaborations. With a focus on neurological disorders and other therapeutic areas, the company has developed breakthrough drugs such as XYREM®, which is used to treat narcolepsy. SK Biopharmaceuticals Co Ltd has built a strong reputation for its cutting-edge research, commitment to scientific excellence, and dedication to improving patients' lives.
SK Biopharmaceuticals Co Ltd has achieved several significant milestones. Firstly, the company successfully developed and obtained approval for its innovative epilepsy treatment, cenobamate, in the United States. This achievement marks a major breakthrough in the treatment of epilepsy. Additionally, SK Biopharmaceuticals Co Ltd has entered into numerous global partnerships and collaborations, expanding its reach in the pharmaceutical industry. The company has also made substantial progress in its pipeline, advancing the development of various neurologic and psychiatric disorders treatments. With these achievements, SK Biopharmaceuticals Co Ltd has further solidified its position as a leading player in the biopharmaceutical sector.
SK Biopharmaceuticals Co Ltd is primarily present in South Korea.
SK Biopharmaceuticals Co Ltd represents values such as innovation, integrity, and collaboration. The company's corporate philosophy revolves around creating innovative solutions to improve the lives of patients worldwide. SK Biopharmaceuticals Co Ltd is committed to conducting business with the utmost integrity, ensuring transparency, and adhering to ethical standards. The company strives to foster a collaborative environment, working together with partners and stakeholders to drive advancements in the biopharmaceutical industry. With a focus on research and development, SK Biopharmaceuticals Co Ltd aims to bring groundbreaking treatments and therapies to patients, reflecting its dedication to improving global healthcare.
Analysts currently set an average price target of 147,198.75 KRW for the SK Biopharmaceuticals Co stock (median: 158,100.00 KRW), implying +99.5 % versus the latest price. The consensus is based on 22 analyst ratings.
22 analysts currently rate the SK Biopharmaceuticals Co stock: 18 recommend buying, 3 holding and 1 selling. For 2026, analysts expect SK Biopharmaceuticals Co to generate revenue of 973.07 B KRW and earnings per share of 4,088.92 KRW.
Converted at the current exchange rate, the SK Biopharmaceuticals Co share trades at 49.07 EUR (73,800.00 KRW).
The SK Biopharmaceuticals Co share (326030.KS) is listed on 1 stock exchanges, including: KOSPI (Seoul) (326030.KS).
SK Biopharmaceuticals Co Ltd (SK biopharm) is a leading South Korean company specializing in the development and commercialization of innovative drugs for the treatment of central nervous system (CNS) disorders and other major diseases. The company is committed to promoting better health for patients worldwide through its research and development. SK biopharm has several business areas, including research and development (R&D), production, and distribution of pharmaceuticals. The R&D division is the core of the company, focusing on the discovery, development, and commercialization of new drugs and therapeutic approaches. SK biopharm invests significantly in R&D and has built a comprehensive research platform that combines expertise in medicine, chemistry, pharmacology, toxicology, and biology. SK biopharm offers a wide range of products available in various countries worldwide. One of the company's key products is the anticonvulsant XCOPRI® (Cenobamate), which is approved in the US, Europe, and China. XCOPRI® was developed to help patients with partial-onset seizures, one of the most common forms of epilepsy. XCOPRI® has proven to be highly effective and safe, showing promising results in clinical trials. Another important product from SK biopharm is the antidepressant Vilazodone (trade name Viibryd), approved for the treatment of depression in adults. Viibryd has shown good efficacy due to its unique dual action on serotonin receptors and serotonin transporters. SK biopharm also has a wide range of products in its R&D pipeline, including new therapies for the treatment of epilepsy, schizophrenia, and pain. SK biopharm pursues a global expansion strategy and has offices in North America, Europe, and Asia. The company has established strategic partnerships with some of the world's leading pharmaceutical companies to accelerate the development and commercialization of its products worldwide. SK biopharm has also formed partnerships with academic institutions and research institutes around the world to drive innovation in medicine. To foster growth, SK biopharm has established a strong corporate culture that promotes innovation, collaboration, and entrepreneurial virtues. The company has an experienced management team and a dedicated research team focused on developing drugs that have the potential to improve the lives of people worldwide. Overall, SK biopharm has an impressive track record in developing and commercializing innovative drugs for a variety of CNS disorders. With its R&D pipeline, wide product range, and strategic partnerships, SK biopharm is well-positioned to continue helping patients worldwide and promoting better health for all.
The expected revenue of SK Biopharmaceuticals Co is 973.07 B KRW. This figure is based on current financial data and reflects the company's business performance.
The expected profit of SK Biopharmaceuticals Co is 320.22 B KRW. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of SK Biopharmaceuticals Co is currently 18.05. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the SK Biopharmaceuticals Co stock.
The price-to-sales ratio (P/S) of SK Biopharmaceuticals Co is currently 5.94. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the SK Biopharmaceuticals Co stock.
The Eulerpool Quality Score for SK Biopharmaceuticals Co is 4/10.
The ISIN of SK Biopharmaceuticals Co is KR7326030004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of SK Biopharmaceuticals Co is 326030.KS. The ticker symbol is used to trade SK Biopharmaceuticals Co shares on the stock exchange.
SK Biopharmaceuticals Co stock
SK Biopharmaceuticals Co Peer Group
SK Biopharmaceuticals Co Ticker
SK Biopharmaceuticals Co FIGI
All fundamentals and in-depth analysis of SK Biopharmaceuticals Co
Our stock analysis for SK Biopharmaceuticals Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SK Biopharmaceuticals Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.